Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 1881-1888

  Jonsson, Håkan ^a   Holmström, Benny ^a,b   Duffy, Stephen W ^c   Stattin, Pär ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

early detection; prostate cancer; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; EARLY DIAGNOSIS; GEOGRAPHY; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN; TREND STUDY;

EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SWEDEN;

EID: 80052026100     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25846     Document Type: Article

References (24)

1. Stark JR, Mucci L, Rothman KJ, Adami HO,. Screening for prostate cancer remains controversial. BMJ 2009; 339: b3601.
2. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG,. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 1397-405. (Pubitemid 38366842)
3. Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A,. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004; 10: 2231-6. (Pubitemid 38445679)
4. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelson A, Bratt O, Damber JE, Hellstrom K, Hellstrom M, Holmberg E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456-77. (Pubitemid 350207540)
5. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J,. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 2007; 51: 659-64. (Pubitemid 46110933)
6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009; 360: 1320-8.
7. Hugosson J, Carlsson S, Aus G, Bergdahl, S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H,. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
9. Andriole GL, Grubb RL, 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med 2009; 360: 1310-9.
10. Melia J, Moss S,. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656-7. (Pubitemid 32929459)
11. Melia J, Moss S, Johns L,. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004; 94: 51-6. (Pubitemid 38980308)
12. Zappa M, Visioli C, Crocetti E, Buonamici C, Baccini A, Taddei S, Ciatto S,. Practice of opportunistic PSA screening in the Florence District. Eur J Cancer Prev 2003; 12: 201-4. (Pubitemid 36683756)
13. Russo A, Autelitano M, Bellini A, Bisanti L,. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen 2002; 9: 179-80. (Pubitemid 36135345)
14. D'Ambrosio G, Samani F, Cancian M, De Mola C,. Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 2004; 13: 383-6. (Pubitemid 39336602)
15. Etzioni R, Berry KM, Legler JM, Shaw P,. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002; 59: 251-5. (Pubitemid 34134526)
16. Drummond FJ, Carsin AE, Sharp L, Comber H,. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Ir J Med Sci 2010; 179: 43-9.
17. Smith DP, Supramaniam R, Marshall VR, Armstrong BK,. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189: 315-8.
18. Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P,. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol 2010; 44: 384-90.
19. Barlow L, Westergren K, Holmberg L, Talback M,. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48: 27-33.
20. Schaedel C, Hjelte L, de Monestrol I, Johannesson M, Kollberg H, Kornfalt R, Holmberg L,. Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden. Clin Genet 1999; 56: 318-22.
21. Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt O, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Tornblom M, Varenhorst E, et al. Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005; 39: 372-9.
22. Gleason DF,. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-9.
23. Jones AP, Haynes R, Sauerzapf V, Crawford SM, Forman D,. Geographical access to healthcare in Northern England and post-mortem diagnosis of cancer. J Public Health 2010; 32: 532-7.
24. Bratt O, Damber JE, Karvinge C, Malm T, Hensjo LO, Hyttsten E,. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening-only for well-informed men]. Lakartidningen 2008; 105: 524-8.